Visugromab RDE is named as a drug or biological intervention in 2 clinical trials in our USA and UK trial registers, 2 of which are recruiting. The lead sponsor is CatalYm GmbH. Registered phase: Phase 2. Conditions studied include Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma; Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07219459 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure (ClinicalTrials.gov ↗) Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound |
Phase 2 | Recruiting |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (ClinicalTrials.gov ↗) Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Unresectable or Metastatic Hepatocellular Carcinoma | 1 |
| Child-Pugh A Hepatocellular Carcinoma | 1 |
| Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound | 1 |
| Metastatic Non-Squamous Non-Small Cell Lung Cancer | 1 |
| Adult Solid Tumor | 1 |
| Lead sponsor | Trials |
|---|---|
| CatalYm GmbH | 2 |
| Register | Visugromab RDE trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Visugromab RDE works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Visugromab RDE (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.